

Invitation to presentation of BioInvent's Year-end report 2021

Lund, Sweden, February 18, 2022 – BioInvent International AB (Nasdaq Stockholm: BINV) invites to a presentation of the Year-end report 2021 and a telephone conference with CEO Martin Welschof. The presentation will be held in English.

When: 2:00 p.m. CET, Wednesday February 23, 2022.

Listen to the presentation: <https://tv.streamfabriken.com/bioinvent-q4-2021>

To participate in the telephone conference, please use the dial-in details shown below:

SE: +46856642704

NE: +31107129163

UK: +443333009270

US: +1646722490

The conference call will be made available on the company's website after the call.

About BioInvent

BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with currently three drug candidates in four ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors, respectively and a fifth program just initiating clinical development. The Company's validated, proprietary F.I.R.S.T™ technology platform simultaneously identifies both targets and the antibodies that bind to them, generating many promising new drug candidates to fuel the Company's own clinical development pipeline or for additional licensing and partnering.

The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com. Follow on Twitter: @BioInvent.

For further information, please contact:

Cecilia Hofvander, Senior Director Investor Relations

Phone: +46 (0)46 286 85 50

Email: cecilia.hofvander@bioinvent.com

BioInvent International AB (publ)

Co. Reg. No. Org nr: 556537-7263

Press Release
18 February 2022 09:30:00 CET



Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com

Attachments

[Invitation to presentation of BioInvent's Year-end report 2021](#)